Patient
ID
tx* Vx* Tx* t0* V0* CD40* T0* ty* Vy* CD4y*
6652 -1 3.9 AZT DDC SQV 0 3.8 179 AZT DDC IDV 2 3.6 132
6665 -2 4.4 3TC AZT SQV 0 4.2 93 3TC AZT IDV 2 3.9 90
6670 -2 5 3TC D4T SQV 0 5 22 3TC D4T IDV 2 3.3 40
6671 -2 4.3 DDC SQV 0 4.7 401 DDC IDV 2 4.4 330
6674 -2 4.9 3TC AZT SQV 0 4.6 286 3TC AZT IDV 2 2.6 322
6678 -2 3.6 3TC AZT SQV 0 3.9 639 3TC AZT IDV 2 2.8 835
6685 -1 4.8 3TC AZT SQV 0 4.8 165 3TC AZT IDV 2 4 178
6686 -1 4.8 3TC AZT SQV 0 4.8 55 3TC AZT IDV 2 3.1 114
6687 -1 3.7 3TC AZT SQV 0 3.7 188 3TC AZT IDV 1 3 184
6689 -4 2.5 AZT DDC SQV 0 2.8 254 AZT DDC IDV 2 2.2 250
6691 -1 4.9 3TC AZT SQV 0 4.8 82 3TC AZT IDV 2 2.5 92
6693 -3 3.1 3TC D4T SQV 0 4 627 3TC D4T IDV 2 2.7 459
6696 -1 3.5 3TC AZT SQV 0 3.7 157 3TC AZT IDV 2 2.3 180
6706 -1 4.3 3TC AZT SQV 0 4.3 284 3TC AZT IDV 1 3.1 233
19255 -140   3TC D4T IDV 0 5.2 18 3TC D4T NFV 13 3.1 91
*T=Treatment, t=time (week), V=viremia; CD4
Table 5: The biological data of the 15 selected patients. ARV resistance was observed at time t0, and a rescue in inhibitory activity was measured at time ty.